Literature DB >> 7709986

Anterior segment ischemia after the Jensen procedure in a 10-year-old patient.

J H Bleik1, G M Cherfan.   

Abstract

PURPOSE/
METHODS: We recently encountered anterior segment ischemia in a young healthy girl with traumatic abducens nerve palsy after the Jensen procedure and ipsilateral recession of the medial rectus muscle. The patient was treated with topical dexamethasone and homatropine 2% and oral prednisone. RESULTS/
CONCLUSION: The patient's condition improved, and six weeks postoperatively, visual acuity was 20/20. As this complication of anterior segment ischemia is potentially serious and unpredictable, we think that an alternative surgical approach should be used when treating patients with muscle palsies.

Entities:  

Mesh:

Year:  1995        PMID: 7709986     DOI: 10.1016/s0002-9394(14)71248-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Recession-resection combined with intraoperative botulinum toxin A chemodenervation for exotropia following subtotal ruptured of medial rectus muscle.

Authors:  Samin Hong; Hyung Keun Lee; Jong Bok Lee; Sueng-Han Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

2.  Vertical rectus muscle union combined with lateral rectus plication for complete abducens nerve palsy.

Authors:  Asli Inal; Birsen Gokyigit; Osman Bulut Ocak; Ebru Demet Aygit; Selcen Celik
Journal:  Int Ophthalmol       Date:  2019-10-23       Impact factor: 2.031

Review 3.  A Review of Transposition Techniques for Treatment of Complete Abducens Nerve Palsy.

Authors:  Mohammad Reza Akbari; Babak Masoomian; Arash Mirmohammadsadeghi; Motahhareh Sadeghi
Journal:  J Curr Ophthalmol       Date:  2021-10-22

4.  Clinical profile and management of sixth nerve palsy in pediatric patients (0-15 years) in Southern India - A hospital-based study.

Authors:  Iva Rani Kalita; K Veena; Fredrick Mouttappa; Priya Sundaralakshmi; Harsh Vardhan Singh
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.